Geode Capital Management
PDSB icon

Geode Capital Management’s PDS Biotechnology PDSB Stock Holding History

Geode Capital Management’s Portfolio PDSB Stock Details PDSB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$399K Buy
660,228
+139,830
+27% +$105K ﹤0.01% 3669
2025
Q4 		$401K Buy
520,398
+38,399
+8% +$34.6K ﹤0.01% 3674
2025
Q3 		$487K Buy
481,999
+64,065
+15% +$75.3K ﹤0.01% 3624
2025
Q2 		$556K Sell
417,934
-19,947
-5% -$27.1K ﹤0.01% 3522
2025
Q1 		$521K Buy
437,881
+20,664
+5% +$29.4K ﹤0.01% 3528
2024
Q4 		$680K Buy
417,217
+2,104
+0.5% +$5.57K ﹤0.01% 3504
2024
Q3 		$1.59M Buy
415,113
+37,142
+10% +$124K ﹤0.01% 3196
2024
Q2 		$1.11M Sell
377,971
-276,214
-42% -$884K ﹤0.01% 3265
2024
Q1 		$2.59M Buy
654,185
+20,981
+3% +$108K ﹤0.01% 3021
2023
Q4 		$3.15M Buy
633,204
+31,844
+5% +$158K ﹤0.01% 2926
2023
Q3 		$3.04M Buy
601,360
+23,966
+4% +$131K ﹤0.01% 2897
2023
Q2 		$2.9M Buy
577,394
+285,141
+98% +$1.87M ﹤0.01% 2983
2023
Q1 		$1.8M Buy
292,253
+12,662
+5% +$104K ﹤0.01% 3079
2022
Q4 		$3.69M Buy
279,591
+9,136
+3% +$64.4K ﹤0.01% 2815
2022
Q3 		$803K Buy
270,455
+25,665
+10% +$109K ﹤0.01% 3503
2022
Q2 		$893K Buy
244,790
+13,373
+6% +$63.6K ﹤0.01% 3481
2022
Q1 		$1.43M Buy
231,417
+23,300
+11% +$145K ﹤0.01% 3433
2021
Q4 		$1.69M Buy
208,117
+23,873
+13% +$257K ﹤0.01% 3458
2021
Q3 		$2.75M Buy
184,244
+6,319
+4% +$78.8K ﹤0.01% 3221
2021
Q2 		$2.23M Buy
177,925
+7,766
+5% +$60.6K ﹤0.01% 3239
2021
Q1 		$774K Buy
170,159
+77,911
+84% +$314K ﹤0.01% 3661
2020
Q4 		$197K Hold
92,248
– – ﹤0.01% 3894
2020
Q3 		$214K Buy
92,248
+8,339
+10% +$23.4K ﹤0.01% 3696
2020
Q2 		$168K Buy
83,909
+65,773
+363% +$73.2K ﹤0.01% 3703
2020
Q1 		$13K Hold
18,136
– – ﹤0.01% 4067
2019
Q4 		$48K Hold
18,136
– – ﹤0.01% 4094
2019
Q3 		$60K Hold
18,136
– – ﹤0.01% 4044
2019
Q2 		$108K Buy
18,136
+6,348
+54% +$41.5K ﹤0.01% 3942
2019
Q1 		$87K Sell
11,788
-3
-0% -$25 ﹤0.01% 3926
2018
Q4 		$75K Hold
11,791
– – ﹤0.01% 3913
2018
Q3 		$193K Sell
11,791
-217
-2% -$3.9K ﹤0.01% 3776
2018
Q2 		$247K Buy
12,008
+1,905
+19% +$39.7K ﹤0.01% 3662
2018
Q1 		$238K Buy
10,103
+648
+7% +$174K ﹤0.01% 3637
2017
Q4 		$1.77M Buy
9,455
+176
+2% +$35.4K ﹤0.01% 2822
2017
Q3 		$1.99M Buy
9,279
+129
+1% +$26.7K ﹤0.01% 2754
2017
Q2 		$1.88M Buy
9,150
+518
+6% +$102K ﹤0.01% 2766
2017
Q1 		$1.57M Buy
8,632
+409
+5% +$81K ﹤0.01% 2787
2016
Q4 		$2.06M Buy
8,223
+155
+2% +$35.2K ﹤0.01% 2612
2016
Q3 		$1.68M Buy
8,068
+4,308
+115% +$854K ﹤0.01% 2664
2016
Q2 		$760K Buy
3,760
+423
+13% +$74.8K ﹤0.01% 3029
2016
Q1 		$610 Buy
3,337
+292
+10% +$52.2K ﹤0.01% 3118
2015
Q4 		$761K Buy
+3,045
New +$982K ﹤0.01% 3056

Other funds holding PDSB

VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
William Blair & Company
William Blair & Company Chicago, Illinois $34.9B AUM 18.88% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
IWA
Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management's PDSB Position: Q1 2026 in Review

Geode Capital Management increased its PDS Biotechnology (PDSB) stake by 27% in Q1 2026, buying an estimated $105K and bringing the position to 660,228 shares worth $399K. The position accounts for ﹤0.01% of the portfolio, ranked #3669.

Geode Capital Management first reported a position in PDSB in Q4 2015 and has held it in 42 quarters since. The position peaked at $3.69M in Q4 2022. 41 funds tracked by Wall St. Rank hold PDSB as of Q1 2026.

  • Geode Capital Management held 660,228 shares of PDS Biotechnology worth $399K as of Q1 2026.
  • Geode Capital Management bought 139,830 PDS Biotechnology shares in Q1 2026, an estimated $105K.
  • PDS Biotechnology made up ﹤0.01% of Geode Capital Management's portfolio in Q1 2026, its #3669 holding.
  • Geode Capital Management first reported a position in PDS Biotechnology in Q4 2015 and has held it in 42 quarters since.
  • Geode Capital Management's PDS Biotechnology position peaked at $3.69M in Q4 2022.
  • 41 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.